News Sentiment
-11.9
Neutral
DATA LIVE
Loading ...
Asset-specific news intelligence
Pfizer Inc.
Aggregated sentiment, estimated market impact and analysis confidence from recent articles linked to this asset. This feature is independent of the overall stock score.
All recent articles have completed sentiment assessments.
As of
Aug 21, 2026, 1:35 AM
News Sentiment
-11.9
Neutral
Estimated Impact
38.9
Weighted estimate of how strongly the analyzed news may affect the asset.
Analysis Confidence
81.5
Confidence in the asset-specific article assessments, not historical model reliability.
Processing state of all articles inside the selected window.
Articles
3
Available
3
Pending
0
Failed
0
Unassessed
0
Latest analyzed article
Aug 20, 2026, 4:39 AM
Counts include only articles with an available assessment.
Positive
0
Neutral
2
Negative
1
High impact
0
Latest article
Aug 19, 2026, 2:08 PM
Showing 1–3 of 3 articles
Protalix reported Q2 2026 revenues of $19.9 million, up from $15.7 million year-over-year, driven by Elfabrio sales through its Chiesi partnership. The company posted net income of $3.8 million ($0.05 per share) and H1 net income of $22.1 million. Full-year 2026 revenue guidance remains $78-83 million. The company maintains a strong cash position of $40.7 million with zero debt and expects PRX-115 Phase 2 RELEASE study top-line results in H2 2027.
Analysis summary
The article reports on Protalix's Q2 2026 earnings and financial guidance, including revenue growth, net income, and upcoming Phase 2 study results. However, the information is about Protalix (PLX), not Pfizer Inc. (PFE), and there is no direct connection or material relevance to Pfizer. The mention of a partnership with Chiesi and drug development is unrelated to Pfizer's operations or assets.
Sentiment
0.0
Impact
20.0
Confidence
85.0
Relevance
30.0
AbbVie and Bristol-Myers Squibb are compared as dividend-paying pharmaceutical investments. AbbVie shows stronger revenue growth (8.6% YoY) driven by Skyrizi and Rinvoq, while Bristol-Myers Squibb faces patent cliff headwinds despite trading at a significant valuation discount. The article recommends AbbVie for long-term investors due to its focused operations, accelerating neuroscience portfolio, and attractive dividend, despite Bristol-Myers Squibb's recovery potential.
Analysis summary
The article compares AbbVie and Bristol-Myers Squibb as pharmaceutical investments, highlighting AbbVie's revenue growth and portfolio strength while noting Bristol-Myers Squibb's patent challenges. Pfizer Inc. is not mentioned in the context of this comparison, and no direct information about Pfizer's performance or strategy is provided. The relevance to Pfizer is limited to the broader sector, a
Eli Lilly's weight-loss pill Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization. The drug offers advantages over competitor Novo Nordisk's Wegovy with no food restrictions. The global obesity drug market is projected to grow from $66 billion in 2025 to $92-200 billion by 2027, presenting significant growth opportunities for multiple manufacturers.
Analysis summary
The article reports that Eli Lilly's weight-loss drug Foundayo received U.K. approval, marking Europe's first GLP-1 oral medication authorization, which could increase competition in the obesity treatment market. This development is moderately negative for Pfizer Inc. as it highlights a competitive advancement by a major player in the same therapeutic space, potentially affecting Pfizer's market份额